Oncolytics is a clinical-stage biotechnology company whose lead product candidate is Pelareorep, an intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies.
A phase Ib window of opportunity study assessing Pelareorep with or without Roche’s Tecentriq, dubbed AWARE-1, is ongoing. The study is designed to enroll 38 patients into five cohorts.
Last month, the Company presented preliminary AWARE-1 data demonstrating viral replication and promotion of inflammation following systemic administration of Pelareorep when combined with Tecentriq.
The interim data from the AWARE-1 breast cancer study is due this quarter.
Oncolytics also has a couple of catalysts to watch out for in the coming year, and some of which are as follows…
— Enrollment in the AWARE-1 breast cancer study is expected to be completed in the first quarter of 2020. — A phase II study of Pelareorep in combination with paclitaxel and avelumab for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative (HR+ / HER2-) metastatic breast cancer, dubbed BRACELET-1, is expected to be initiated next quarter (Q1, 2020). — The final data from the AWARE-1 trial is anticipated in the second quarter of 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.